Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.

Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, Siddiqui J, Demichelis F, Moeller P, Bismar TA, Kuefer R, Fullen DR, Johnson TM, Greenson JK, Giordano TJ, Tan P, Tomlins SA, Varambally S, Rubin MA, Maher CA, Chinnaiyan AM.

Nat Med. 2010 Jul;16(7):793-8. doi: 10.1038/nm.2166.

2.

Gene methylation in gastric cancer.

Qu Y, Dang S, Hou P.

Clin Chim Acta. 2013 Sep 23;424:53-65. doi: 10.1016/j.cca.2013.05.002. Review.

3.

Landscape of gene fusions in epithelial cancers: seq and ye shall find.

Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM.

Genome Med. 2015 Dec 18;7:129. doi: 10.1186/s13073-015-0252-1. Review.

5.

ETS gene fusions in prostate cancer.

Clark JP, Cooper CS.

Nat Rev Urol. 2009 Aug;6(8):429-39. doi: 10.1038/nrurol.2009.127. Review.

PMID:
19657377
6.

Recurrent gene fusions in prostate cancer: their clinical implications and uses.

Hessels D, Schalken JA.

Curr Urol Rep. 2013 Jun;14(3):214-22. doi: 10.1007/s11934-013-0321-1. Review.

PMID:
23625457
7.

The discovery and application of gene fusions in prostate cancer.

Morris DS, Tomlins SA, Montie JE, Chinnaiyan AM.

BJU Int. 2008 Aug;102(3):276-82. doi: 10.1111/j.1464-410X.2008.07665.x. Review.

8.

ETS fusion genes in prostate cancer.

Gasi Tandefelt D, Boormans J, Hermans K, Trapman J.

Endocr Relat Cancer. 2014 May 6;21(3):R143-52. doi: 10.1530/ERC-13-0390. Review.

9.

Epigenetic regulation in human melanoma: past and future.

Sarkar D, Leung EY, Baguley BC, Finlay GJ, Askarian-Amiri ME.

Epigenetics. 2015;10(2):103-21. doi: 10.1080/15592294.2014.1003746. Review.

10.

New insight into BRAF mutations in cancer.

Dhomen N, Marais R.

Curr Opin Genet Dev. 2007 Feb;17(1):31-9. Review.

PMID:
17208430
11.

MEK and RAF inhibitors for BRAF-mutated cancers.

Belden S, Flaherty KT.

Expert Rev Mol Med. 2012 Oct 12;14:e17. doi: 10.1017/erm.2012.11. Review.

PMID:
23058743
12.

Morphologic features of carcinomas with recurrent gene fusions.

Qi M, Li Y, Liu J, Yang X, Wang L, Zhou Z, Han B.

Adv Anat Pathol. 2012 Nov;19(6):417-24. doi: 10.1097/PAP.0b013e318273baae. Review.

PMID:
23060067
13.

Fusion in the ETS gene family and prostate cancer.

Narod SA, Seth A, Nam R.

Br J Cancer. 2008 Sep 16;99(6):847-51. doi: 10.1038/sj.bjc.6604558. Review.

14.

Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.

Smalley KS, Nathanson KL, Flaherty KT.

Cancer Res. 2009 Apr 15;69(8):3241-4. doi: 10.1158/0008-5472.CAN-08-4305. Review.

15.

BRAFV600E: implications for carcinogenesis and molecular therapy.

Cantwell-Dorris ER, O'Leary JJ, Sheils OM.

Mol Cancer Ther. 2011 Mar;10(3):385-94. doi: 10.1158/1535-7163.MCT-10-0799. Review.

16.

[TMPRSS2-ETS gene fusion in prostate cancer].

Perner S, Schmidt FH, Hofer MD, Kuefer R, Rubin M.

Urologe A. 2007 Jul;46(7):754-60. Review. German.

PMID:
17458530
17.

Regulation of the MIR155 host gene in physiological and pathological processes.

Elton TS, Selemon H, Elton SM, Parinandi NL.

Gene. 2013 Dec 10;532(1):1-12. doi: 10.1016/j.gene.2012.12.009. Review.

PMID:
23246696
18.

Recurrent rearrangements in prostate cancer: causes and therapeutic potential.

White NM, Feng FY, Maher CA.

Curr Drug Targets. 2013 Apr;14(4):450-9. Review.

19.

Molecular pathways: targeting ETS gene fusions in cancer.

Feng FY, Brenner JC, Hussain M, Chinnaiyan AM.

Clin Cancer Res. 2014 Sep 1;20(17):4442-8. doi: 10.1158/1078-0432.CCR-13-0275. Review.

20.

Recurrent gene fusions in prostate cancer.

Kumar-Sinha C, Tomlins SA, Chinnaiyan AM.

Nat Rev Cancer. 2008 Jul;8(7):497-511. doi: 10.1038/nrc2402. Review.

Items per page

Supplemental Content

Support Center